Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + cadonilimab + chemotherapy for first-line advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400087450Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Jul 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, cadonilimab, oxaliplatin, tegafur + gimeracil + oteracil, fluorouracil and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Hospital of Lanzhou University. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
fruquintinibcadonilimaboxaliplatintegafur + gimeracil + oteracilfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400087450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087450.